Comparison of Gleason score of Prostate Cancer at Ultrasound/MRI Fusion Target Biopsy vs. Systematic Transrectal Ultrasound Guided Biopsy with Final Gleason score at Radical Prostatectomy
- 20 October 2022
- journal article
- Published by Peertechz Publications Private Limited in Archive of Urological Research
- Vol. 6 (2), 017-021
- https://doi.org/10.17352/aur.000039
Abstract
Purpose: To compare accuracy in predicting final Gleason Grade Group (GGG) of Prostate Cancer (PCa) of US/MRI fusion guided target (fBx) vs. systematic Transrectal Ultrasound-Guided (TRUS) biopsy, using histopathologic analysis at prostatectomy as the gold standard. Materials and methods: After obtaining IRB approval, we retrospectively reviewed records of patients who underwent Radical Prostatectomy (RP) from January 2014 through May 2019 with prior US/MRI fusion guided target or TRUS biopsy. The rates of upgrading (RP GGG > BX GGG), downgrading (RP GGG < BX GGG), and concordance (RP GGG = BX GGG) were compared between the fBx and TRUS groups. Age, PSA, PSA density, and prostate volume were also noted for all patients. Statistical analysis was utilized to assess the data. Results: A total of 348 men with complete clinical data were included in this study. The rate of downgrading and upgrading in the fBx group was less than in the TRUS biopsy group (14% vs. 19.6%, and 13.2% vs. 19.6%, respectively). The concordance rate was higher in the US-MR fBx group (72.9% vs. 60.7%, p < 0.05)) across all GGG. Notably, lower rates of concordance were found for GGG 1 (24.1%) and GGG 4 (3.6%) in the TRUS Bx group. Patients who underwent US-MR fBx had higher average PSA (9.4 vs. 6.5 ng/ml), higher PSA density (0.3 vs. 0.2 ng/ml2), and lower prostate volume (31 vs. 42 cc). Additionally, biopsy results showed a lower rate of GGG 1 (3.1% vs. 13.2%) and a higher rate of GGG 5 (14.7% vs. 5.5%) in the US-MR fBx group. Conclusions: Target biopsy has a higher GGG concordance compared to TRUS biopsy (72.9% vs. 60.7%, p < 0.05). In addition, there was less downgrading or upgrading of final PCa GGG in the fBx groups compared to TRUS Bx (14% vs. 19.6%, 13.2% vs. 19.6%, respectively). This finding may have important implications for treatment decisions.Keywords
This publication has 22 references indexed in Scilit:
- Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion DeviceJournal of Urology, 2013
- Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy CohortEuropean Urology, 2012
- Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy Improves Cancer Detection Following Transrectal Ultrasound Biopsy and Correlates With Multiparametric Magnetic Resonance ImagingJournal of Urology, 2011
- Gleason score 7 screen‐detected prostate cancers initially managed expectantly: outcomes in 50 menBJU International, 2009
- Optimal Approach for Prostate Cancer Detection as Initial Biopsy: Prospective Randomized Study Comparing Transperineal Versus Transrectal Systematic 12-Core BiopsyUrology, 2008
- MRI-Guided Biopsy of the Prostate Increases Diagnostic Performance in Men with Elevated or Increasing PSA Levels after Previous Negative TRUS BiopsiesEuropean Urology, 2006
- USE OF EXTENDED PATTERN TECHNIQUE FOR INITIAL PROSTATE BIOPSYJournal of Urology, 2005
- Extended Peripheral Zone Biopsy Schemes Increase Cancer Detection Rates and Minimize Variance in Prostate Specific Antigen and Age Related Cancer Rates: Results of a Community Multi-Practice StudyJournal of Urology, 2003
- Gleason score on biopsy: is it reliable for predicting the final grade on pathology?BJU International, 2002
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateThe New England Journal of Medicine, 1987